PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2015 | 2 | 2 | 136-141
Article title

Doskonalenie form leku w celu osiągnięcia skutecznej farmakoterapii

Content
Title variants
EN
Optimization of dosage forms to achieve effective pharmacotherapy
Languages of publication
PL
Abstracts
EN
The aim of the development of ocular delivery systems is to improve the therapeutic efficacy and to facilitate the drug administration by the patient. The current research studies in the area of the ophthalmic preparations primarily focus on the development of the dispersed systems, i.e., micro- and nanoparticles, liposomes, submicron emulsions, microemulsions as well as the solid dosage forms such as implants, inserts and minitablets. The possibilities provided by the pharmaceutical technology in the area of the dosage forms development are presented on the example of the cyclosporin A.
PL
Celem poszukiwania nowych rozwiązań w zakresie preparatów do oczu jest poprawa skuteczności terapeutycznej, a także łatwa aplikacja leku przez chorego. Obecne badania dotyczące preparatów do oczu mają służyć przede wszystkim opracowaniu postaci leku w formie układów rozproszonych, tj. mikro- i nanocząstek, liposomów, emulsji submikronowych, mikroemulsji, a także stałych form leku, tj. implantów, insertów, minitabletek. Na przykładzie cyklosporyny A przedstawiono możliwości technologii farmaceutycznej.
Discipline
Publisher
Journal
Year
Volume
2
Issue
2
Pages
136-141
Physical description
References
  • 1. Farmakopea Polska, wyd. X. LUMINA Grupa Wydawnicza, Warszawa 2014.
  • 2. Jachowicz R. Postać leku. Optymalizacja leków doustnych i do oczu w nowoczesnej technologii farmaceutycznej. Wydawnictwo Lekarskie PZWL, Warszawa 2013; 362-426.
  • 3. Souza JG, Dias K, Pereira TA, et al. Topical delivery of ocular therapeutics: carrier systems and physical methods. J Pharm Pharmacol 2013; 66: 507-530.
  • 4. Di Tommaso C, Behar-Cohen F, Gurny R, Moller M. Colloidal systems for the delivery of cyclosporin A to the anterior segment of the eye. Ann Pharm Fr 2011; 69: 116-123.
  • 5. Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 2003; 56: 307-318.
  • 6. Yavuz B, Pehlivan SB, Ünlü N. An overview on dry eye treatment: approaches for cyclosporin A delivery. ScientificWorldJournal 2012; 194848.
  • 7. Allergan I, 2010. Restasis (Cyclosporine a Ophthalmic Emulsion) 0.05% [online: http://www.allergan.com/assets/pdf/restasis_ pi.pdf ].
  • 8. Kurkov SV, Loftsson T. Cyclodextrins. Int J Pharm 2013; 457: 167-180.
  • 9. Alghadyan AA, Peyman GA, Khoobehi BK. Liposome-bound cyclosporine: aqueous and vitreous level after subconjunctival injection. Int. Ophtalmol. 1988; 12: 101-104.
  • 10. Jachowicz R, Czech A, Jamróz W. Mikro- i nanocząstki w terapii okulistycznej. Farm Pol 2009; 65: 285-290.
  • 11. Calvo P, Sanchez A, Martinez J, et al. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm Res 1996; 13: 311-315.
  • 12. de Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001; 224: 159-168.
  • 13. Xie L, Shi W, Wang Z, et al. Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glicolide polymer. Cornea 2001; 20: 748-752.
  • 14. Abdelkader H, Pierscionek B, Alany RG. Novel in situ gelling ocular films for the opioid growth factor-receptor antagonistnaltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies. Int J Pharm 2014; 477: 631-642.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-112fc29c-e593-4b8c-a196-e69e2367da38
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.